Microdosing7 min read

What Microdosing Research Actually Shows (Including the Placebo Problem)

Microdosing has a great story. Take a tiny amount of psilocybin every few days and feel a bit brighter, calmer or more creative, without anything that looks like a trip. Millions of people have tried it, and plenty swear by it. But what does the science say? The answer is more nuanced, and more interesting, than either fans or critics usually admit. Here's a friendly, evidence-first tour.

First, what counts as a microdose?

A microdose is a dose small enough that you shouldn't feel obviously altered. For dried Psilocybe cubensis, people commonly use somewhere around 0.05 to 0.25 g, though potency varies a lot by strain and batch. Many people prefer measured microdose capsules for consistency. If you notice visual changes, strong body sensations or a clear "high", you've gone past a microdose. Our Microdosing 101 covers the basics.

Why microdosing is hard to study

Before we get to the findings, it helps to understand why this research is tricky:

The effects people report are subtle: mood, focus, energy, creativity. These are exactly the kinds of things that expectation can shift.
Most people who sign up for studies already believe microdosing works, which can colour how they report their experience.
Doses in the real world are inconsistent, especially with whole mushrooms.
Psilocybin is a controlled substance in most countries, which makes large, well-controlled trials expensive and slow.

This is why researchers distinguish between observational studies (watching what people do and asking how they feel) and placebo-controlled studies (where some people unknowingly take a dummy dose). Both are useful, but only the second kind can tell us whether the drug itself is causing the changes.

The observational studies: promising signals

Some of the earliest systematic data came from Vince Polito and Richard Stevenson at Macquarie University in Australia, published in PLOS ONE in 2019. They followed 98 microdosers over six weeks, with daily ratings and before-and-after questionnaires. Participants reported feeling better across many measures on dose days, though those boosts mostly faded within a day or two. Over the six weeks, depression and stress scores went down and mind-wandering decreased. Interestingly, a measure of neuroticism went slightly up. The authors were clear about the limits: participants were recruited from pro-microdosing communities and there was no placebo.

In 2021, Joseph Rootman and colleagues published a large survey in Scientific Reports with more than 8,700 respondents from 84 countries, using a mobile app. Psilocybin was by far the most common microdosing substance, and over half of microdosers "stacked" it with other things, most often lion's mane mushroom or niacin. Among people who reported mental health concerns, microdosers showed somewhat lower levels of depression, anxiety and stress than non-microdosers. The effects were small, and because this was a snapshot survey of self-selected people, it can't show cause and effect.

These studies are valuable. They tell us what people are doing and what they experience. They just can't separate the effects of psilocybin from the effects of hope, routine and attention.

The placebo-controlled studies: a reality check

The self-blinding study (Szigeti et al., 2021)

The most famous placebo-controlled microdosing study came from Balázs Szigeti and colleagues at Imperial College London, published in eLife in 2021. It used a clever "self-blinding" design. Participants who were already planning to microdose prepared their own capsules, some with their usual microdose and some empty, then mixed them up and tracked them with barcodes so they didn't know which they were taking on a given day.

It's worth noting that this study used LSD rather than psilocybin, but its lessons apply broadly. Around 191 people started the study. Over four weeks, both the microdose and the placebo groups reported improvements in wellbeing, mood and other measures, and the differences between them were small or absent. People's guesses about whether they had taken a real dose predicted their experience better than what they had actually taken. As Szigeti put it in Imperial's press release, "the improvements may not be due to the pharmacological action of the drug but can instead be explained by the placebo effect."

Microdosing with actual mushrooms (Cavanna et al., 2022)

A team led by Federico Cavanna and Enzo Tagliazucchi in Argentina published a double-blind, placebo-controlled study in Translational Psychiatry in 2022 using real dried Psilocybe cubensis. Thirty-four participants took 0.5 g of dried mushrooms during one week and a placebo during another. Many participants correctly guessed which week was which, and the stronger subjective effects of the active dose showed up only among those who guessed correctly. The study found no improvements in creativity, wellbeing or cognition from microdosing, with a few small changes pointing towards mild cognitive impairment. The authors concluded that expectation plays a major role in the benefits people attribute to microdosing.

Note the dose: 0.5 g of dried mushrooms sits at the upper edge of what many people call a microdose. That's partly why so many participants could tell which week they were in.

Other controlled work

Other placebo-controlled studies, including a preregistered field and lab study by Marschall and colleagues published in 2022, have also found little evidence that psilocybin microdosing improves emotion-related symptoms beyond placebo. The overall picture from controlled research so far is consistent: expectations explain a large share of the reported benefits.

What about stacking?

Many microdosers combine psilocybin with other supplements, a practice called stacking. The best-known version, associated with mycologist Paul Stamets, pairs psilocybin with lion's mane mushroom and niacin (vitamin B3). In the Rootman survey, lion's mane was the most common addition. The idea is appealing, but there are no controlled human trials showing that the stack works better than psilocybin alone, or better than placebo. Lion's mane has its own small body of research, which we cover in our functional mushrooms guide. Niacin at higher amounts can cause a harmless but uncomfortable skin flush. If you're curious, treat stacking as an experiment, add one thing at a time and keep notes so you know what is doing what.

So, is microdosing "just placebo"?

Not necessarily, and here's the nuance. A few things are worth holding at once:

The placebo effect is real. People in these studies genuinely felt better. The question is whether psilocybin adds anything on top.
Controlled studies so far have been small and short, typically a few weeks. They may miss subtle or long-term effects.
Doses varied, and some studies used LSD instead of psilocybin.
The routine itself, including paying attention to your mood, journalling, and setting intentions, may be part of why people feel better.

The honest position today is that the evidence for microdosing benefits beyond placebo is weak, and more rigorous, longer research is needed. If you choose to microdose, go in with curiosity rather than certainty.

How to microdose thoughtfully, given the evidence

If you're going to try it, you can borrow some ideas from the researchers:

Keep the dose small. Start at the low end, around 0.05 to 0.1 g of dried mushroom or the smallest capsule size, and adjust slowly.
Follow a schedule with rest days. Popular options are compared in our schedules guide.
Track your experience. Our journal template gives you a quick daily check-in.
Try a self-check. Some people run their own informal blind by having a friend prepare identical capsules, some empty, and then compare their notes. It's a fun way to see how much expectation is doing.
Take breaks. A couple of weeks off every month or two helps you notice what's actually changing.

What's normal and what isn't

Normal on a microdose: a subtle lift in mood or energy, slight restlessness, a mild change in appetite, or nothing noticeable at all. Some people notice a little yawning or a faint body buzz.

Signs you've taken too much: visual changes, giggles you can't explain, trouble concentrating, feeling spaced out. Lower the dose next time and don't drive or work with machinery that day.

Signs to stop and talk to a professional: worsening anxiety, low mood, insomnia, or any unusual thoughts.

Who should skip microdosing

Microdosing is still taking psilocybin. Avoid it if you have a personal or family history of psychosis or bipolar disorder, are pregnant or breastfeeding, have a heart condition, or take lithium, MAOIs, tramadol or antidepressants unless a doctor says otherwise. Read our medications guide. Psilocybin is a controlled substance in Canada, and you must be 19 or older to shop with us.

The bottom line

Microdosing research is young. Observational studies show people who microdose often report feeling better; controlled studies suggest much of that comes from expectation. Both can be true at once. Keep your expectations realistic, your doses small and your notes honest, and you'll learn more about yourself either way. Browse microdose products, the Microdose Starter Kit, or our full microdosing guide.

Sources

This guide is general information, not medical or legal advice. If you have health questions, talk to a health professional.